Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities

16 Feb 2022

Abstract excerpt

Gliomas are the most common malignant primary brain tumor in adults. Despite advances in multimodality therapy, incorporating surgery, radiotherapy, systemic therapy, tumor treating fields and supportive care, patient outcomes remain poor, especially in glioblastoma where median survival has remained static at around 15 months, for decades. Low-grade gliomas typically harbor isocitrate dehydrogenase (IDH)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35205750
DOI: 10.3390/cancers14041003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors in Glioma: A Review of Therapeutic OpportunitiesPMID 35205750Read ↗

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical DevelopmentSemantic proximity Read ↗

Therapeutic Application of PARP Inhibitors in Neuro-Oncology.Semantic proximity Read ↗

The Study on the Expression Level of PARP-1 in Glioma and Computational Screening of PARP-1 InhibitorsSemantic proximity Read ↗

Current and promising treatment strategies in glioma.Semantic proximity Read ↗

Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP InhibitorsSemantic proximity Read ↗

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Semantic proximity Read ↗

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma MultiformeSemantic proximity Read ↗

PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.Semantic proximity Read ↗

Olaparib: A Chemosensitizer for the Treatment of GlioblastomaSemantic proximity Read ↗

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trialsSemantic proximity Read ↗

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?Semantic proximity Read ↗

Enhanced efficacy of combined HDAC and PARP targeting in glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.